Characteristics of RA patients included in the study
| Patient no. . | Age, y . | Sex . | Treatment . | Disease duration, y . | Sample type . |
|---|---|---|---|---|---|
| 1 | 69 | F | MTX, CQ, CS | 2 | SF |
| 2 | 21 | F | Anti–TNF-α, MTX, CS | 7 | SF |
| 3 | 68 | M | MTX, CS | < 1 | SF |
| 4 | 28 | M | CsA | 1 | SF |
| 5 | 74 | M | — | 1 | SF |
| 6 | 37 | F | — | 3 | SF |
| 7 | 48 | F | CS | 16 | SF |
| 8 | 37 | F | — | 3 | SF |
| 9 | 84 | F | — | 46 | SF |
| 10 | 63 | F | CS | 2 | SF |
| 11 | 59 | M | NSAIDs | < 1 | SF |
| 12 | 40 | F | Anti–TNF-α | 13 | SF |
| 13 | 73 | F | — | 1 | SM |
| 14 | 68 | F | — | 10 | SM |
| 15 | 30 | F | MTX, CSs | 1 | SM |
| 16 | 74 | F | CSs, leflunomide | 2 | SM |
| 17 | 52 | F | Aza, CQ | 27 | SM |
| Patient no. . | Age, y . | Sex . | Treatment . | Disease duration, y . | Sample type . |
|---|---|---|---|---|---|
| 1 | 69 | F | MTX, CQ, CS | 2 | SF |
| 2 | 21 | F | Anti–TNF-α, MTX, CS | 7 | SF |
| 3 | 68 | M | MTX, CS | < 1 | SF |
| 4 | 28 | M | CsA | 1 | SF |
| 5 | 74 | M | — | 1 | SF |
| 6 | 37 | F | — | 3 | SF |
| 7 | 48 | F | CS | 16 | SF |
| 8 | 37 | F | — | 3 | SF |
| 9 | 84 | F | — | 46 | SF |
| 10 | 63 | F | CS | 2 | SF |
| 11 | 59 | M | NSAIDs | < 1 | SF |
| 12 | 40 | F | Anti–TNF-α | 13 | SF |
| 13 | 73 | F | — | 1 | SM |
| 14 | 68 | F | — | 10 | SM |
| 15 | 30 | F | MTX, CSs | 1 | SM |
| 16 | 74 | F | CSs, leflunomide | 2 | SM |
| 17 | 52 | F | Aza, CQ | 27 | SM |
MTX indicates methotrexate; CQ, chloroquine; CSs, corticosteroids; CsA, cyclosporine A; TNF-α, tumor necrosis factor-α; NSAIDs, nonsteroidal anti-inflammatory drugs; Aza, azathioprine; SF, synovial fluid; and SM, synovial membrane.